MVision AI

Our partner Meditest will be at #GFRU2026 in Lyon (Mar 26–27) at booth A03. Visit the booth to learn how MVision Workspace+® supports efficient #radiotherapy preparation. *CE-marked (CE 2797) medical device under EU MDR 2017/745; Workspace+ is not available in all markets.

MVision AI will be at #ASMIRT2026 in Hobart, Australia (Mar 26–29) with partner AlphaXRT at booth 34–36. Learn how our solutions support more efficient radiotherapy preparation workflows while promoting consistent quality and clinical oversight. #ASMIRT2026 #Radiotherapy

Clinical implementation is the focus of the AAPM Spring Clinical Meeting, March 21–24 in Orlando. MVision AI will be at table 109 to talk about how AI can support radiotherapy teams and bring greater consistency to treatment preparation. #Radiotherapy #MedicalAI

⏳ One week to go! Join our webinar with Intellimed on the latest innovations in radiotherapy workflows & see how AI-powered tools support accuracy & consistency in RT. 📅 Mar 24 | 15:00–16:00 (Swiss time) 🔗 bit.ly/3PG5fY1 #RTWorkflow #Switzerland

MVision AI was honoured to present on AI-assisted radiation therapy treatment preparation at the 39th Annual Meeting of the Japan High Precision External Beam Radiotherapy Group in Tokyo. Thank you for the valuable discussions that followed. #Radiotherapy #MedicalAI #JASTRO

MVision AI will be at the RSS Scientific Meeting 2026 in Orlando, March 19–21. Stop by table 20 to learn how we are applying AI to support radiotherapy teams and improve consistency in treatment preparation. #Radiotherapy #MedicalAI

MVision AI will exhibit at the 38th TROG Annual Scientific Meeting (Mar 17–20, Melbourne) with our partner AlphaXRT. Visit our booth to meet the team & learn how AI-driven solutions support advances in radiation oncology. #TROG2026 #AIinHealthcare

We'll attend the 39th Japan High Precision External Beam Radiotherapy Meeting in Tokyo on March 14. Founder & CEO Mahmudul Hasan will take part in a presentation on AI-Assisted Radiation Therapy Treatment Preparation. *Technologies shown are not approved or for sale in Japan.

MVision AI is honored to be one of the sponsors of ISROI Meeting 2026 in St. Gallen, Switzerland on March 6 — a focused forum on AI, data science, and IT security in radiation oncology. #RadiationOncology #AI

In our latest ‘Expert Perspectives’ interview, Principal Physicist Michael Roche (CUH/UCC Cancer Centre) shares how AI contouring reduced CT-to-treatment timelines while keeping clinicians in control. 👉 eu1.hubs.ly/H0s8zXx0 #Radiotherapy #AIinHealthcare

Cancer in the US continues to place growing pressure on patients, clinicians, and healthcare systems. Our updated article looks at access, cost, telemedicine, and the growing role of AI in radiotherapy planning. 👉 bit.ly/3OwfXQA #RadiationOncology #AIinHealthcare

Independent research at the 2026 BIR Radiotherapy & Oncology Meeting reported strong dosimetric agreement between MVision AI & expert contours in head & neck planning, with no tolerance breaches. This supports the responsible, evidence-based use of AI in patient care.

New case study from The Royal Marsden & ICR explores a simulation-free workflow for Elekta Unity MRI-guided adaptive prostate RT. Results show diagnostic MRI could support reference planning while maintaining plan quality and clinical standards. 👉 bit.ly/4aGX1pu

Workspace+, our AI-powered platform for #radiotherapy, has received market approval in Australia and is now approved for clinical use. 👉 bit.ly/4kG6MJi #MedTech *CE-marked (CE 2797) medical device under EU MDR 2017/745; this product is not available in all markets.

MVision AI is pleased to take part in the Moffitt Radiation Oncology Conference (ROC), Feb 12–14 in Tampa. Looking forward to connecting with leaders in #RadiationOncology and discussing how AI and innovation continue to shape precision #CancerCare. #AIinHealthcare

AMSTRO 2026 wrapped up yesterday. Thank you to everyone who visited us at Booth #2 & joined conversations on the future of radiotherapy. We also appreciated the strong engagement around Founder and CEO Mahmudul Hasan’s panel on sustainable cancer systems. #AMSTRO2026 #MVisionAI

We will be at BIR 2026 in London, 12–13 Feb at The Minster Building. Visit us with Xiel Ltd. at table 17 & hear Hassan Hassan present Workspace+ in the Minster Forum. Workspace+ is a CE-marked (CE 2797) medical device under EU MDR 2017/745; it is not available in all markets.

Mahmudul Hasan, Founder & CEO of MVision AI, will join the AMSTRO 2026 panel “From Innovation to Impact” on Feb 7, 9:50–10:20 AM at Zayed University Convention Center, Dubai. A timely discussion on sustainable cancer systems. #AMSTRO2026 #MVisionAI

Today we celebrate #WorldCancerDay. The 2025-2027 theme, “United by Unique,” highlights how progress in cancer care depends on collaboration. At MVision AI, we support #radiotherapy teams with AI-driven tools that help improve consistency and efficiency in care delivery.

We are heading to AMSTRO 2026 in Dubai, Feb 6–8 at Zayed University Convention Center. Visit MVision AI at booth #2 to meet Mahmudul Hasan and Rachel Buckingham and see our AI solutions in action.